Status:
COMPLETED
Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population
Lead Sponsor:
Université de Sherbrooke
Collaborating Sponsors:
Société des Produits Nestlé (SPN)
Conditions:
Parkinson Disease
Alzheimer Disease
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3...
Eligibility Criteria
Inclusion
- Alzheimer's or parkinson disease diagnostic
- Stable medication associated with the disease
- Able to consent
- Presence of an accompanying person for the first and last visit.
- Ability to read and talk in French
Exclusion
- MMSE \< 20
- MCT or coconut oil supplementation
- Coconut allergy
- Cannabis, THC or CBD consumption
- Excessive alcohol consumption
- Physical activity 3x/week
- Presence of an metallic object in the body
- Impossibility to lay in dorsal decubitus for 40 minutes
- Cardiac disease
- Any uncontrolled disease that could interfer with the project.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 27 2024
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT04322461
Start Date
May 1 2022
End Date
May 27 2024
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de recherche sur le vieillissement
Sherbrooke, Quebec, Canada, J1H 4C4